News

Under the terms of the agreement, Bharat Serums and Vaccines (BSV) will develop and manufacture the product for marketing by Actavis in Europe, Australia, South Africa and Turkey.

Partners at the University of Washington’s Center for Industrial and Medical Ultrasound, the Texas A&M University’s Institute for Preclinical Studies and Siemens Corporate Research (SCR) will work together

Mr Benton will succeed William Claypool, who is leaving Phoenix Data Systems to start a pharmaceutical development consulting company, Pennmark Associates. Most recently, Mr Benton was COO of

As part of this plan, Vertellus is proceeding with the engineering and permitting work to build a 3-cyanopyridine production unit at Nantong with capacity of 7,000 metric tons

Frank DiCosmo, president and CEO of Covalon, said: “Peter has significant experience in the medical devices industry, having previously served as director of finance for Stryker Canada. “Peter

Ms Mullarky has joined Tekmira effective immediately and will have responsibility for strategic planning and business development including securing additional licensing and collaborative R&D agreements for Tekmira’s technology.

The company has achieved its primary clinical endpoint for the trial, autograft engraftment comparable to the standard of care. No adverse or serious adverse events were deemed to

POT-4 is a complement inhibitor, which shuts down the complement activation cascade that could otherwise lead to local inflammation, tissue damage and upregulation of angiogenic factors such as

ResponseDX: Colon and ResponseDX: Lung are proprietary PCR-based tests in a panel, which include the analysis of KRAS mutation and serve to help physicians with therapeutic treatment decisions